Skip to main content

Table 2 Factors influencing outcomes to afatinib. The clinical factors that influenced PFS in our cohort

From: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

  No. of events/ patients Median PFS, months (95% CI) Log-rank p-value Hazard ratio (95% CI) Cox model p-value
Total 60 / 120 11.9 (10.3, 19.3) NA NA NA
Sex
 Male 35 / 62 13.3 (9.0, 20.1) 0.344 1 0.343
 Female 25 / 58 11.9 (10.3, 25.7)   0.78 (0.47, 1.31)  
Age at diagnosis, years
  < 65 45 / 86 11.9 (9.7, 19.3) 0.791 1 0.790
  ≥ 65 15 / 34 11.7 (5.3, UD)   0.92 (0.51, 1.66)  
Smoking history
 Never 42 / 91 14.5 (10.7, 22.1) 0.017 1 0.025
 Former / Current 18 / 29 7.9 (3.5, 17.4)   1.94 (1.12, 3.38)  
EGFR mutation type
 Exon 19 deletion 40 / 83 15.0 (10.9, 22.1) < 0.001 1 0.008
 L858R 12 / 27 11.2 (6.5, UD)   1.19 (0.62, 2.28)  
 Others 6 / 8 4.5 (1.7, UD)   5.51 (2.23, 13.64)  
Brain metastasis at start of afatinib
 No 40 / 80 15.0 (10.9, 20.6) 0.140 1 0.153
 Yes 20 / 40 7.9 (5.1, 13.3)   1.50 (0.87, 2.57)a  
Starting doseb
 30 mg 23 / 58 10.7 (6.5, UD) 0.105 1 0.113
 40 mg 37 / 61 15.0 (10.8, 20.6)   0.63 (0.36, 1.11)  
Amongst patients with no brain metastasis:
Starting doseb
 30 mg 10 / 35 UD 0.897 1 0.898
 40 mg 30 / 44 15.0 (10.8, 22.1)   0.95 (0.44, 2.04)  
Amongst patients with brain metastasis:
Starting dose
 30 mg 13 / 23 5.3 (3.1, 10.7) 0.040 1 0.041
 40 mg 7 / 17 13.3 (6.5, UD)   0.39 (0.15, 0.99)  
Amongst patients on 30 mg starting dose:
Brain metastasis
 No 10 / 35 UD 0.007 1 0.010
 Yes 13 / 23 5.3 (3.1, 10.7)   2.96 (1.29, 6.79)  
Amongst patients on 40 mg starting dose:
Brain metastasis
 No 30 / 44 15.0 (10.8, 22.1) 0.567 1 0.558
 Yes 7 / 17 13.3 (6.5, UD)   0.79 (0.34, 1.80)a  
  1. PFS Progression-free survival, NA Not applicable, UD Undefined
  2. aNon-proportional hazards
  3. bOne patient had a starting dose of 20 mg. This patient was excluded